Baird Upgrades Tandem Diabetes Care to Outperform, Raises Price Target to $30

Benzinga · 1d ago
Baird analyst Jeff Johnson upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Neutral to Outperform and raises the price target from $18 to $30.